Melanoma drug combo study halted before full results
NCT ID NCT01604889
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, ipilimumab and epacadostat, in people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if adding epacadostat to standard treatment improved survival. However, the study was stopped early for business reasons, and only the first safety phase was completed. About 50 adults took part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Los Angeles, California, United States
-
Study site
Miami, Florida, United States
-
Study site
Tampa, Florida, United States
-
Study site
Chicago, Illinois, United States
-
Study site
Durham, North Carolina, United States
-
Study site
Philadelphia, Pennsylvania, United States
-
Study site
Pittsburgh, Pennsylvania, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?